Ireland· IE-PA-EU/1/23/1758/001-002
Tevimbra 100 mg concentrate for solution for infusion
A tislelizumab product containing tislelizumab, registered in Ireland by BeiGene Ireland Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Tislelizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF09 (tislelizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Tislelizumab · ATC L01FF09
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of tislelizumab costs, country by country.
Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tislelizumab · price per daily dose (9.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$204.40
The record
At a glance
HPRA (Ireland)- Active substance
- Tislelizumab
- Manufacturer
- BeiGene Ireland Limited
- Country
- Ireland (IE)
- ATC code
- L01FF09
- ATC class
- Tislelizumab
- Defined daily dose
- 9.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1758/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tislelizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTevimbra 100 mgBeOne Medicines Ireland
- CzechiaTEVIMBRABeOne Medicines Ireland Limited, Dublin
- FinlandTevimbraBeOne Medicines Ireland Limited
- IcelandTevimbraBeigene Ireland Limited
- NorwayTevimbraBeOne Medicines Ireland Limited
- PolandTizveniBeiGene Ireland Ltd.
- SwedenTevimbra 100 mg Koncentrat till infusionsvätska, lösningBeOne Medicines Ireland Limited
- United StatesTEVIMBRABeOne Medicines USA, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tevimbra
- Norway · Tevimbra
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6e7d4389-42d4-4807-8dd3-750234071ed8 GET /v1/drugs/6e7d4389-42d4-4807-8dd3-750234071ed8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01",
"L01FF09"
],
"strength": null,
"pa_number": "EU/1/23/1758/001-002",
"substances": [
"Tislelizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "15/09/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about tislelizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.